Send to

Choose Destination
Nanomedicine (Lond). 2012 Dec;7(12):1877-93. doi: 10.2217/nnm.12.157.

Liposome-based delivery system for vaccine candidates: constructing an effective formulation.

Author information

The University of Queensland, School of Chemistry & Molecular Biosciences, St Lucia, QLD 4072, Australia.

Erratum in

  • Nanomedicine (Lond). 2013 Feb;8(2):312. Giddam, Ashwin Kumar [corrected to Giddam, Ashwini Kumar].


The discovery of liposomes in 1965 by Bangham and coworkers changed the prospects of drug delivery systems. Since then, the application of liposomes as vaccine delivery systems has been studied extensively. Liposomal vaccine delivery systems are made up of nano- or micro-sized vesicles consisting of phospholipid bilayers, in which the bioactive molecule is encapsulated/entrapped, adsorbed or surface coupled. In general, liposomes are not immunogenic on their own; thus, liposomes combined with immunostimulating ligands (adjuvants) or various other formulations have been used as vaccine delivery systems. A thorough understanding of formulation parameters allows the design of effective liposomal vaccine delivery systems. This article provides an overview of various factors that influence liposomal immunogenicity. In particular, the effects of vesicle size, surface charge, bilayer composition, lamellarity, pegylation and targeting of liposomes are described.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center